Mirum (MIRM) director uses options, sells 2,000 pre-planned shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Mirum Pharmaceuticals director Saira Ramasastry exercised options and sold the resulting shares in a planned transaction. On April 15, 2026, she exercised a stock option to acquire 2,000 shares of Mirum common stock at $23.51 per share, from a fully vested option. The same day, she sold 2,000 common shares in an open-market transaction at $96.90 per share, leaving 0 shares of common stock reported as directly owned after the sale. The filing notes the activity occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the trades were pre-arranged.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,000 shares ($193,800)
Net Sell
3 txns
Insider
Ramasastry Saira
Role
Director
Sold
2,000 shs ($194K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 2,000 | $0.00 | -- |
| Exercise | Common Stock | 2,000 | $23.51 | $47K |
| Sale | Common Stock | 2,000 | $96.90 | $194K |
Holdings After Transaction:
Stock Option (right to buy) — 2,000 shares (Direct);
Common Stock — 2,000 shares (Direct)
Footnotes (1)
- Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025. The stock option is fully vested.
Key Figures
Options exercised: 2,000 shares
Exercise price: $23.51 per share
Shares sold: 2,000 shares
+3 more
6 metrics
Options exercised
2,000 shares
Stock option exercise on April 15, 2026
Exercise price
$23.51 per share
Strike price of stock option exercised
Shares sold
2,000 shares
Open-market sale on April 15, 2026
Sale price
$96.90 per share
Price for common stock sale
Post-transaction holdings
0 shares
Common stock directly owned after sale
10b5-1 plan adoption date
September 18, 2025
Date trading plan was adopted
Key Terms
Rule 10b5-1 Plan, Stock Option (right to buy), derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested financial
"The stock option is fully vested."
FAQ
What insider transaction did Mirum Pharmaceuticals (MIRM) director Saira Ramasastry report?
Director Saira Ramasastry reported exercising stock options for 2,000 Mirum shares and selling all 2,000 shares. The exercise price was $23.51 per share and the shares were sold at $96.90 per share in an open-market transaction.
Was the Mirum (MIRM) insider sale by Saira Ramasastry under a Rule 10b5-1 plan?
Yes. The filing states the reported transaction occurred under a Rule 10b5-1 trading plan adopted by Saira Ramasastry on September 18, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing.
What type of derivative security did Saira Ramasastry exercise for Mirum (MIRM)?
She exercised a fully vested stock option covering 2,000 Mirum common shares at a $23.51 exercise price. The option, described as a “Stock Option (right to buy),” originally had an expiration date in June 2032 before being fully exercised.